Patents by Inventor Yan Lou

Yan Lou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BCL-2 INHIBITORS
    Publication number: 20260152513
    Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neurodegenerative disease with these compounds.
    Type: Application
    Filed: January 17, 2025
    Publication date: June 4, 2026
    Inventors: Yi Chen, Yan Lou
  • BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY
    Publication number: 20260021095
    Abstract: The present disclosure provides certain bifunctional compounds that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: June 20, 2023
    Publication date: January 22, 2026
    Inventors: Yan LOU, Zhiyong YU
  • BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY
    Publication number: 20250367193
    Abstract: The present disclosure provides certain bifunctional compounds containing substituted pyrimidine derivatives substituted at the 4-position with a cyclic group that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: June 21, 2023
    Publication date: December 4, 2025
    Inventors: Yan LOU, Zhiyong YU
  • PROCESSES OF MAKING 3-FLUORO-5-(((1S,2AR)-1,3,3,4,4 PENTAFLUORO-2A-HYDROXY-2,2A,3,4-TETRAHYDRO-1H-CYCLOPENTA[CD]INDEN-7-YL)OXY)BENZONITRILE AND POLYMORPHS THEREOF
    Publication number: 20250361203
    Abstract: The present disclosure provides certain processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro- 1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile (Compound 1) and certain polymorphs thereof. Also provided are pharmaceutical compositions comprising a crystalline polymorph form of Compound 1 and processes for preparing such polymorph forms.
    Type: Application
    Filed: August 7, 2025
    Publication date: November 27, 2025
    Inventors: Charles M. COOK, Jiping FU, Yigang HE, Yan LOU, Rongzhen CHEN, Yan DONG
  • TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS
    Publication number: 20250340508
    Abstract: The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are Hypoxia Inducible Factor 2? (HIF-2?) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2?. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: July 15, 2025
    Publication date: November 6, 2025
    Inventors: Jiping FU, Yan LOU, Yigang HE
  • Process of preparing 3-fluoro-5(((1R,2AR)-3,3,4,4-tetrafluoro-1,2A-dihydroxy-2,2A,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrile
    Patent number: 12435034
    Abstract: Disclosed herein are processes for preparing certain intermediates useful in the synthesis of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 2, 2023
    Date of Patent: October 7, 2025
    Assignee: NIKANG THERAPEUTICS, INC.
    Inventors: Jiping Fu, Yan Lou, Yigang He, Yuetao Shi, Peng Zhou, Xingxing Li
  • Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof
    Patent number: 12415779
    Abstract: The present disclosure provides certain processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile (Compound 1) and certain polymorphs thereof. Also provided are pharmaceutical compositions comprising a crystalline polymorph form of Compound 1 and processes for preparing such polymorph forms.
    Type: Grant
    Filed: October 11, 2022
    Date of Patent: September 16, 2025
    Assignee: NIKANG THERAPEUTICS, INC.
    Inventors: Charles M. Cook, Jiping Fu, Yigang He, Yan Lou, Rongzhen Chen, Yan Dong
  • Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases
    Patent number: 12410190
    Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
    Type: Grant
    Filed: May 3, 2023
    Date of Patent: September 9, 2025
    Assignee: Newave Pharmaceutical Inc.
    Inventors: Yi Chen, Yan Lou
  • Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
    Patent number: 12391642
    Abstract: The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are Hypoxia Inducible Factor 2? (HIF-2?) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2?. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: July 12, 2023
    Date of Patent: August 19, 2025
    Assignee: NiKang Therapeutics, Inc.
    Inventors: Jiping Fu, Yan Lou, Yigang He
  • Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
    Patent number: 12331026
    Abstract: The present disclosure provides certain sulfonamido derivatives that are Cyclin-dependent kinase 2 (CDK2) inhibitors of Formula (I): for the treatment of diseases treatable by inhibition of CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: March 24, 2023
    Date of Patent: June 17, 2025
    Assignee: NiKang Therapeutics, Inc.
    Inventor: Yan Lou
  • CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES
    Publication number: 20250179090
    Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
    Type: Application
    Filed: December 6, 2024
    Publication date: June 5, 2025
    Inventors: Yi Chen, Yan Lou
  • Immunoproteasome inhibitors
    Patent number: 12312370
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: October 17, 2023
    Date of Patent: May 27, 2025
    Assignee: Principia Biopharma Inc.
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors
    Patent number: 12264167
    Abstract: The present disclosure provides certain fused tricyclic ring derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: April 1, 2025
    Assignee: NIKANG THERAPEUTICS, INC.
    Inventors: Jiping Fu, Yan Lou, Yigang He
  • BCL-2 INHIBITORS
    Publication number: 20250051329
    Abstract: The disclosure includes compounds of Formula (I) wherein W, R1, R2, R3, R4, R5, R6, m, n, L, and Z1, are defined herein. Also disclosed is a method for treating a neoplastic disease and autoimmune disease with these compounds.
    Type: Application
    Filed: May 30, 2024
    Publication date: February 13, 2025
    Inventors: Yi Chen, Yan Lou
  • COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY
    Publication number: 20250018049
    Abstract: The present disclosure provides certain bifunctional compounds that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin proteosome pathway and are therefore useful for the treatment of diseases mediated by CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: December 21, 2021
    Publication date: January 16, 2025
    Inventors: Jiping FU, Yan LOU
  • BCL-2 INHIBITORS
    Publication number: 20240425520
    Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
    Type: Application
    Filed: April 22, 2024
    Publication date: December 26, 2024
    Inventors: Yi Chen, Yan Lou
  • 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
    Patent number: 12171741
    Abstract: The present disclosure provides certain 2,3-dihydrobenzo[b]thiophene compounds that are Hypoxia Inducible Factor 2? (HIF-2?) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2?. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: December 24, 2024
    Assignee: NiKang Therapeutics, Inc.
    Inventors: Jiping Fu, Yan Lou, Yigang He
  • Indane derivatives as hypoxia inducible factor-2(?) inhibitors
    Patent number: 12077506
    Abstract: The present disclosure provides certain indane compounds that are Hypoxia Inducible Factor 2? (HIF-2?) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2?. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: September 3, 2024
    Assignee: NiKang Therapeutics, Inc.
    Inventors: Jiping Fu, Yan Lou, Yigang He
  • ALKYLIDENE DERIVATIVES AS KRAS INHIBITORS
    Publication number: 20240287100
    Abstract: The present disclosure provides certain alkylidenyl derivatives that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: January 12, 2024
    Publication date: August 29, 2024
    Inventors: Jiping FU, Yan LOU, Yongfeng SUN
  • Immunoproteasome inhibitors
    Patent number: 12024531
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: July 2, 2024
    Assignee: Principia Biopharma Inc.
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein